Simcere Pharmaceutical | Sustainability Performance
Develops, manufactures, and markets pharmaceutical products.
1995
China
5,001 - 10,000 employees
Pharmaceuticals
$1B - 10B in revenue
$100M - 500M in profitability
Submit or report inaccurate dataDownload Company InsightsⓘBy downloading this report, you'll receive the most insightful and detailed analysis of the company's sustainability performance, compared to its peers. It includes key industry trends, carbon and energy intensity, nature impact, social metrics, and an in-depth look at key risks and controversies.
Sustainability Ranking & Industry Benchmark
#10783
Overallⓘ#769
in Chinaⓘ#261
in PharmaceuticalsⓘSustainability Maturity
ⓘSustainability Intent
ⓘOverview
Financial Data
Business performanceCapital & innovationAnalyst projections
Controversy level
- Simcere Pharmaceutical Group Limited, Chinese pharmaceutical major (cancer/CV), has faced sustained Chinese NMPA enforcement scrutiny over alleged inadequate disclosure of multiple oncology product quality at multiple Chinese production facilities, plus the contested 2024 Chinese government NRDL (National Reimbursement Drug List) price negotiations affecting Hong Konglisted institutional shareholders.
